Answering the common challenges facing real-world CAR T-cell therapies 

During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session entitled 'The ins and outs of CAR T-cells in the real world'.
Here, we share the presentation of Professor Michael Hudecek, University Hospital Würzburg, Würzburg, DE, about answers to common challenges in CAR T-cell therapy.
Hudecek begins by discussing the issues of patient access and the scalability of CAR T-cell therapy, drawing geographical comparisons on the types of CAR-T studies performed in different regions. Referencing real-world data, Hudecek describes how limited patient access affects the implementation of CAR T-cell treatments before elaborating on the logistical challenges of CAR T-cell therapies. In answer to these challenges and to improve the manufacturing process of CAR T-cells, Hudecek highlights three key areas of development; the use of artificial intelligence, virus-free gene transfer, and in vivo gene transfer.
This activity was supported through an educational grant from Bristol Myers Squibb.
Visit www.lymphomahub.com for more information on this topic.